InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（2 笔）
内部人交易记录
首席执行官已披露买入
1
已披露卖出
2
T+90 胜率
100%
T+90 平均收益
+72.2%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the complete record of transactions filed by O'Connor Daniel J., 首席执行官. Insider active across 6 companies, notably ONCOSEC MEDICAL Inc. Aggregated, 8 reports have been published. Breakdown: 1 buy · 2 sells. Total volume traded: €478k. History available since 30 April 2021. The latest transaction was filed on 11 December 2023 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to O'Connor Daniel J.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
48,202 股Common StockSEC:0000950170-24-028190:0
750,000 股0Common StockSEC:0000950170-23-069446:0
50,012 股@ US$9.82100.0% 占其流量Common StockSEC:0000950170-23-056943:0
2,750,000 股0Ordinary SharesSEC:0001209191-23-026093:0
1,377,598 股0Common StockSEC:0001493152-22-035477:0
16,000 股@ €0.5742100.0% 占其流量Common StockSEC:0001136261-22-000249:0
标准退出：2022年8月30日 (T+90)
42,005 股0Class A Common StockSEC:0001213900-22-011644:0
3,172 股@ US$4.86100.0% 占其流量Common StockSEC:0001493152-21-010454:0
8 条申报中的 8 条
About O'Connor Daniel J.
Daniel J. O'Connor is the Chief Executive Officer and President of OncoSec Medical Inc., Larkspur Health Acquisition Corp., and Seelos Therapeutics, Inc. He is responsible for the strategic and operational direction of these companies, overseeing product development and research initiatives. With a strong background in the biopharmaceutical sector, he is committed to promoting innovation and developing treatments that meet patient needs.
